Skip to main content

Table 1 Baseline clinical characteristics and parameters of the patients

From: Plasma erythropoietin level and heart failure in patients undergoing peritoneal dialysis: a cross-sectional study

Total, n 39
Female, n (%) 11 (28.2)
Age (years) 63.23 ± 12.52
BMI (kg/m2) 23.81 ± 3.70
Diatbetes, n (%) 25 (64.1)
Diabetic nephritis as primary disease, n (%) 19 (48.7)
Nephrosclerosis, n (%) 5 (12.8)
PD vintage (months) 19.41 ± 21.73
D/P ratio 0.687 ± 0.143
D/D0 ratio 0.384 ± 0.106
Urinary volume (ml/day) 899.2 ± 452.8
Dialysate dose (ml/day) 5051.3 ± 1601.0
RASi, n (%) 28 (71.8)
Beta blocker, n (%) 9 (23.1)
Statin, n (%) 15 (38.5)
Diuretic (%) 30 (76.9)
Iron supplementation, n (%) 9 (23.1)
IVSd (mm) 9.795 ± 2.166
PWd (mm) 9.974 ± 2.194
LVDd (mm) 48.54 ± 7.181
LVDs (mm) 32.18 ± 7.904
LVMI (g/m2) 120.7 ± 38.99
EF (%) 61.62 ± 13.28
E/A 0.747 ± 0.250
Cardiac index 3.062 ± 1.334
Peritoneal Kt/V urea 4.825 ± 1.679
Renal Kt/V urea 3.816 ± 3.679
Weekly Kt/V urea 1.711 ± 0.757
Peritoneal CCr (L/week/1.73 m2) 3.623 ± 1.569
Renal CCr (L/week/1.73 m2) 5.771 ± 5.690
Weekly CCr (L/week/1.73 m2) 66.65 ± 34.43
Cr at starting PD (mg/dL) 7.368 ± 2.893
eGFR at starting PD (mL/ min/1.73 m2) 6.885 ± 2.293
ESA dose (μg/month) 127.3 ± 78.46
Plasma erythropoietin (mIU/mL) 7.933 ± 5.494
RBC (*104/μL) 360.7 ± 43.23
Hb (g/dL) 10.72 ± 1.266
Ht (%) 32.76 ± 3.805
Reticulocyte (‰) 10.33 ± 5.075
Fe (μg/dL) 88.18 ± 30.58
TIBC (μg/dL) 248.4 ± 41.77
Ferritin (ng/mL) 158.9 ± 153.4
TSAT 0.360 ± 0.133
CTR (%) 49.57 ± 5.435
NT-proBNP (pg/mL) 11839.8 ± 21293.2
Lactate (mg/dL) 10.85 ± 5.386
Ca (mg/dL) 8.438 ± 0.821
P (mg/dL) 5.818 ± 1.612
iPTH (pg/mL) 250.3 ± 117.4
Na (mEq/L) 138.8 ± 3.639
K (mEq/L) 4.564 ± 0.788
Cl (mEq/L) 101.6 ± 4.951
BUN (mg/dL) 62.20 ± 13.93
Cr (mg/dL) 9.591 ± 3.438
TP (g/dL) 6.241 ± 0.612
Alb (g/dL) 3.269 ± 0.404
CRP (mg/dL) 0.459 ± 2.144
sβ2MG (mg/L) 24.43 ± 9.657
Venous pH 7.360 ± 0.040
NYHA classification
 I, n (%) 30 (76.9)
 II, n (%) 9 (23.1)
 III and IV None
  1. BMI body mass index, RASi renin–angiotensin system inhibitor, PD peritoneal dialysis, D/P ratio dialysate creatinine to plasma creatinine ratio, D/D ratio dialysate glucose to initial dialysate glucose ratio, RASi intake of renin–angiotensin system inhibitor, IVSd interventricular septum diameter, PWd posterior wall diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, LVMI left ventricular mass index, EF left ventricle ejection fraction, E/A early to late diastolic transmitral flow velocity, CCr creatinine clearance, eGFR estimated glomerular filtration rate, ESA erythropoiesis-stimulating agent, RBC red blood cell, Hb hemoglobin, Ht hematocrit, Fe serum ferrum, TIBC total iron binding capacity, CTR cardiothoracic ratio, NT-proBNP N-terminal pro-brain natriuretic peptide, Ca serum calcium, P serum phosphorus, iPTH intact parathyroid hormone, Na serum sodium, K serum potassium, Cl serum chlorine, BUN blood urea nitrogen, Cr serum creatinine, TP serum total protein, Alb serum albumin, CRP C-reactive protein, sβ2MG serum beta 2 microglobulin, NYHA the New York Heart Association
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us